S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
66,000% upside on tiny biotech? (Ad)
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
66,000% upside on tiny biotech? (Ad)
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
66,000% upside on tiny biotech? (Ad)
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
66,000% upside on tiny biotech? (Ad)
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
66,000% upside on tiny biotech? (Ad)
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
66,000% upside on tiny biotech? (Ad)
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
66,000% upside on tiny biotech? (Ad)
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
66,000% upside on tiny biotech? (Ad)
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
66,000% upside on tiny biotech? (Ad)
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
66,000% upside on tiny biotech? (Ad)
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
66,000% upside on tiny biotech? (Ad)
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
66,000% upside on tiny biotech? (Ad)
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
NASDAQ:ISEE

IVERIC bio - ISEE Stock Forecast, Price & News

$21.05
-1.72 (-7.55%)
(As of 02/8/2023 12:00 AM ET)
Add
Compare
Today's Range
$20.93
$23.23
50-Day Range
$18.67
$23.99
52-Week Range
$8.85
$24.56
Volume
3.08 million shs
Average Volume
1.83 million shs
Market Capitalization
$2.54 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.20

IVERIC bio MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.78 Rating Score
Upside/​Downside
24.5% Upside
$26.20 Price Target
Short Interest
Bearish
9.36% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.39mentions of IVERIC bio in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$1.65 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.43) to ($1.48) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.33 out of 5 stars

Medical Sector

977th out of 1,026 stocks

Pharmaceutical Preparations Industry

477th out of 504 stocks

ISEE stock logo

About IVERIC bio (NASDAQ:ISEE) Stock

IVERIC bio, Inc. operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in Parsippany, NJ.

Receive ISEE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IVERIC bio and its competitors with MarketBeat's FREE daily newsletter.

ISEE Stock News Headlines

An All-In-One Guide for Trading Metals
So many want to add metals to their portfolio. Metals can be a great way to protect your money and hedge against market downturns. But first, you need to know how. Download our FREE Guide to Metals Futures today from RJO Futures to get the information that you need to know to trade futures in metals. pixel
Iveric bio: Building Momentum Around Zimura, Rate Buy
Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation. pixel
IVERIC bio, Inc. (ISEE) Q3 2022 Earnings Call Transcript
IVERIC bio: Q3 Earnings Insights
IVERIC bio's Earnings: A Preview
IVERIC bio Whale Trades For October 05
Why Iveric Bio Stock Is Skyrocketing This Week
Analyst Ratings for IVERIC bio
Iveric Bio to Present at Upcoming Investor Conferences
See More Headlines
Receive ISEE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IVERIC bio and its competitors with MarketBeat's FREE daily newsletter.

ISEE Company Calendar

Last Earnings
11/08/2021
Today
2/08/2023
Next Earnings (Estimated)
2/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ISEE
Fax
N/A
Employees
94
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$26.20
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+24.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

Net Income
$-114,520,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.14 per share

Miscellaneous

Free Float
117,463,000
Market Cap
$2.54 billion
Optionable
Optionable
Beta
1.09

Key Executives

  • Glenn P. SblendorioGlenn P. Sblendorio
    Chief Executive Officer & Director
  • Pravin U. DugelPravin U. Dugel
    President & Director
  • Keith WestbyKeith Westby
    Chief Operating Officer & Senior Vice President
  • David F. Carroll
    Chief Financial Officer, Treasurer & Senior VP
  • Xiao Ping Dai
    Chief Technical Officer













ISEE Stock - Frequently Asked Questions

Should I buy or sell IVERIC bio stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IVERIC bio in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ISEE shares.
View ISEE analyst ratings
or view top-rated stocks.

What is IVERIC bio's stock price forecast for 2023?

9 Wall Street analysts have issued 12-month target prices for IVERIC bio's shares. Their ISEE share price forecasts range from $8.00 to $35.00. On average, they predict the company's share price to reach $26.20 in the next year. This suggests a possible upside of 24.5% from the stock's current price.
View analysts price targets for ISEE
or view top-rated stocks among Wall Street analysts.

How have ISEE shares performed in 2023?

IVERIC bio's stock was trading at $21.41 on January 1st, 2023. Since then, ISEE shares have decreased by 1.7% and is now trading at $21.05.
View the best growth stocks for 2023 here
.

When is IVERIC bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our ISEE earnings forecast
.

How were IVERIC bio's earnings last quarter?

IVERIC bio, Inc. (NASDAQ:ISEE) released its earnings results on Monday, November, 8th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.06. During the same period in the prior year, the business earned ($0.27) EPS.

What is Glenn Spina's approval rating as IVERIC bio's CEO?

6 employees have rated IVERIC bio Chief Executive Officer Glenn Spina on Glassdoor.com. Glenn Spina has an approval rating of 41% among the company's employees. This puts Glenn Spina in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of IVERIC bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IVERIC bio investors own include Pfizer (PFE), Inovio Pharmaceuticals (INO), Novavax (NVAX), Maxar Technologies (MAXR), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Alibaba Group (BABA), Cisco Systems (CSCO) and Kinross Gold (KGC).

What is IVERIC bio's stock symbol?

IVERIC bio trades on the NASDAQ under the ticker symbol "ISEE."

Who are IVERIC bio's major shareholders?

IVERIC bio's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Skandinaviska Enskilda Banken AB publ (0.66%), Emerald Advisers LLC (0.63%), Emerald Mutual Fund Advisers Trust (0.50%), Thornburg Investment Management Inc. (0.24%), Swiss National Bank (0.23%) and UBS Group AG (0.22%). Insiders that own company stock include Anthony S Gibney, Calvin W Roberts, Christopher Paul Simms, David Francis Carroll, David R Guyer, Glenn Sblendorio, Keith Westby and Pravin Dugel.
View institutional ownership trends
.

How do I buy shares of IVERIC bio?

Shares of ISEE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IVERIC bio's stock price today?

One share of ISEE stock can currently be purchased for approximately $21.05.

How much money does IVERIC bio make?

IVERIC bio (NASDAQ:ISEE) has a market capitalization of $2.54 billion. The company earns $-114,520,000.00 in net income (profit) each year or ($1.34) on an earnings per share basis.

How can I contact IVERIC bio?

IVERIC bio's mailing address is ONE PENN PLAZA 35TH FLOOR, NEW YORK NY, 10119. The official website for the company is ivericbio.com. The company can be reached via phone at (609) 474-6755 or via email at kathy.galante@ivericbio.com.

This page (NASDAQ:ISEE) was last updated on 2/9/2023 by MarketBeat.com Staff